Reports Q4 revenue $38.8M, consensus $34.43M. "In 2022, AYVAKIT became the standard of care for patients with advanced systemic mastocytosis in the U.S., and we continued to solidify our global leadership in mast cell disorders. Today, we are at the precipice of a pivotal moment in Blueprint’s history as we near a potential FDA approval of AYVAKIT for a much broader population of patients with indolent SM, which will enable us to address the significant medical needs of SM patients and create a critical inflection point in our growing revenue stream. In addition to our commercial execution, we advanced additional clinical development programs and continued to bolster our financial strength through our strategic financing and business development," said CEO Kate Haviland. "In 2023, Blueprint Medicines has a diversity of fundamental value drivers that position us well on the path to achieve our 2027 Blueprint for Precision at Scale and translate the promise of precision medicine into reality for thousands of patients globally."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
- Blueprint Medicines: FDA puts partial clinical hold on the Phase 1/2 VELA trial
- Blueprint Medicines to present results from PIONEER trial of AYVAKIT
- Citi opens ‘negative Catalyst Watch’ on Blueprint Medicines into data
- Blueprint Medicines’ Supplemental NDA for Ayvakit approved by FDA